NEW YORK, NY / ACCESS Newswire / January 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ:ZBIO). Investors who purchased Zenas securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ZBIO.
Zenas Investigation Details
On January 5, 2026, Zenas issued a press release announcing "results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)." Although Zenas characterized the results as "positive," analysts noted that the drug’s reported efficacy likely fell short of the relevant threshold for commercial viability. Following this news, Zenas’s stock price fell $17.89 per share, or 51.86%, to close at $16.61 per share on January 5, 2026.
What’s Next for Zenas Investors?
If you are aware of any facts relating to this investigation or purchased Zenas securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ZBIO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Zenas Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zenas Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_471846729/2457/2026-01-07T16:13:51